Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel

Clopidogrel (Clop) is oxidized by cytochrome P450s (CYPs) to an active thiol metabolite, Clop‐AM, to inhibit platelet activation and aggregation. As an irreversible inhibitor of CYP2B6 and CYP2C19, clopidogrel may inhibit its own metabolism after long‐term administration. The study compared the pharmacokinetic profiles of clopidogrel and its metabolites in rats receiving a single or a 2 week administration of Clop. The mRNA and protein levels of hepatic clopidogrel‐metabolizing enzymes and their enzymatic activities were analyzed to explore their contribution to any altered plasma exposure of Clop and its metabolites. The results showed that long‐term treatment with clopidogrel significantly decreased the AUC (0‐t) and C max values of Clop‐AM in rats, accompanied with markedly impaired catalytic activities of Clop‐metabolizing CYPs including CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4. It suggests that consecutive administration of Clop to rats decreases hepatic CYPs activities, which may, in turn, inhibit clopidogrel metabolism and then reduce Clop‐AM plasma exposure. Therefore, long‐term treatment with clopidogrel has the potential to reduce its anti‐platelet activity and to increase the risk of drug–drug interaction.